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Abstract  
 
Disturbances in the hippocampal glutamate (Glu)/N-methyl-d-aspartate (NMDA) 
system have been implicated in the pathophysiology of bipolar disorder (BD). Here 
we aim to provide a targeted integration of two measures of glutamatergic functioning 
in BD; the association between mismatch negativity (MMN) measured over temporal 
lobes (temporal MMN) and frontal lobes (frontocentral MMN) and in vivo 
hippocampal-Glu measured via proton magnetic resonance spectroscopy (1H-MRS). 
Thirty-three patients with BD and 23 matched controls underwent a two-tone passive, 
duration deviant MMN paradigm and 1H-MRS. Levels of Glu/creatine (Cr) in the 
hippocampus were determined. Pearson’s correlations were used to determine 
associations between MMN and Glu/Cr. In controls MMN amplitude was positively 
associated with Glu/Cr at the left temporal site. We did not find any significant 
associations with Glu/Cr and frontocentral MMN nor did we find any significant 
associations in BD. The results provide further insight into the neurophysiology of 
MMN, with evidence supporting the role of hippocampal-Glu signalling through the 
NMDA receptor in temporal MMN. Our data also demonstrate that Glu/Cr regulation 
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of MMN is dampened in BD which may indicate a lack of tightly regulated 
hippocampal NMDA functioning. These findings provide insight into the underlying 
basis of glutamatergic transmission disturbances implicated in the disorder. 
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1. Introduction 
There is evidence to suggest that disturbances in hippocampal glutamate (Glu) in 
bipolar disorder (BD) may be associated with its pathology (Ng et al., 2009; Scarr et 
al., 2003). The hippocampal-Glu disturbances recognized in BD are largely evidenced 
by abnormalities in the expression and signalling through N-methyl-d-aspartate 
(NMDA) receptors (Ng et al., 2009). The specifics of these findings are inconsistent 
however, with a report of decreased NMDA receptor mRNA expression (Law and 
Deakin, 2001), one showing no change in NMDA receptor density but reduced 
channel opening (Beneyto et al., 2007) and another showing reductions in receptor 
density (Scarr et al., 2003). Overall the neuropharmacology of the relationship 
between Glu, NMDA receptors and the hippocampus in BD is considered to be an 
area that requires further research, with recommendations of targeted integration 
between investigatory methods (Ng et al., 2009).  
Mismatch negativity (MMN) is an event-related potential, consistently 
implicated in schizophrenia neurophysiology (Naatanen and Kahkonen, 2009; 
Umbricht and Krljes, 2005), and gaining increased attention in BD literature (Chitty 
et al., 2013; Kaur et al., 2012a; Kaur et al., 2011), with our meta-analysis supporting a 
decreased frontal MMN in BD compared to controls (Chitty et al., 2013) Evidence 
suggests that Glu signalling through the NMDA receptor channel is necessary for 
MMN elicitation (Javitt et al., 1995; Javitt et al., 1996), hence this brain potential is 
thought to provide a unique avenue to probe disturbances in receptor functioning 
(Javitt et al., 2011). There is extensive evidence that implicates two sources of MMN, 
a frontocentral source and a temporal source (Baldeweg et al., 2002; Deouell et al., 
1998; Giard et al., 1990, Naatanen et al., 2007; Rinne et al., 2000). It is generally 
accepted that these two sources of MMN reflect distinct components of the response 
(Garrido et al., 2009; Naatanen et al., 2007; Rinne et al., 2000). The majority of 
research into the modulation of MMN by NMDA receptor agonists has looked at 
frontal MMN, leaving only speculations as to the role of the glutamatergic/NMDA 
receptor system in temporal MMN (Kenemans and Kahkonen, 2011).  
Furthermore, spatial resolution of MMN is poor, so while there is limited 
evidence specifically implicating the hippocampus in its generation, multichannel 
magnetoencephalography and electroencephalography (EEG) studies have identified 
the temporal cortex as a source of MMN generation (Giard et al., 1995; Giard et al., 
1990; Rinne et al., 2000). Recently an animal study has identified the hippocampus as 
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a source of MMN, which was elicited within the same latency range as auditory 
cortical MMN responses (Ruusuvirta et al., 2013). In addition, the hippocampus is 
strongly implicated in NMDA receptor-mediated long-term potentiation (Bennett, 
2000), which is integral to the formation of memory and cortical plasticity, both of 
which are neural processes hypothesised as being indexed by MMN (Baldeweg and 
Hirsch, 2014). Indeed, temporally generated MMN is hypothesised to be the result of 
matching incoming stimuli to the sensory memory trace (Giard et al., 1990).  
Glu is the brain’s most abundant excitatory neurotransmitter, and the primary 
agonist at NMDA receptors. Measurement of in vivo Glu via proton magnetic 
resonance spectroscopy (1H-MRS) has enabled advancements of our understanding of 
Glu abnormalities in BD, however Glu concentration measured this way has a number 
of limitations to its interpretation. Importantly, 1H-MRS is a static measure that does 
not take into account dynamic changes in the metabolite (e.g. intracellular vs 
extracellular) and hence, does not reflect glutamatergic activity (Ongur et al., 2008). 
Additionally, depending on field strength of the scan, 1H-MRS studies vary between 
reporting Glu versus Glx, the overlapping resonance of Glu and glutamine. The latter, 
associated with obvious difficulties in determining whether the results reflect Glu, 
glutamine or glial-cycling abnormalities. With those limitations in mind, our recent 
meta-analyses of 1H-MRS studies found Glu/Glx to be increased in the frontal lobes 
in BD (Chitty et al., 2013). Studies looking at hippocampal-Glu have not been 
investigated extensively, though a recent 1H-MRS study of first mania episode 
patients did not find any differences in this region compared to controls (Gigante et 
al., 2014). 
Here we aim to provide a targeted integration of two measures of 
glutamatergic functioning in BD, by exploring the association between MMN 
recorded frontally and temporally and in vivo hippocampal-Glu (and Glx for 
comparison), and comparing this relationship to controls. It is entirely plausible that a 
brain region could have an abnormality in Glu levels, which is then related to an 
abnormal MMN. While the two measures cannot be directly compared, we propose 
that concurrently interpreting Glu concentration and NMDA receptor output 
(measured by MMN) will provide a more holistic approach to investigating 
glutamatergic activity in the disorder. We aimed to address this gap in the 
understanding of in vivo glutamatergic/NMDA receptor abnormalities in BD. We 
hypothesise that in controls a positive association will exist between hippocampal-Glu 
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and temporal MMN due to an increased availability of Glu in the hippocampus (a 
temporal region) to bind to the NMDA receptor, and hence elicit a larger temporal 
MMN. We do not expect to find an association between frontocentral MMN and 
hippocampal-Glu, due not only to the spatial location of the hippocampus, but also 
due to the hippocampal role in plasticity and sensory memory which reflect temporal 
MMN rather than frontal MMN. In BD we propose that a positive relationship 
between hippocampal-Glu and temporal MMN may be absent, given our meta-
analysis suggests that BD have increased levels of Glu and decreased MMN 
amplitudes (albeit frontally) (Chitty et al., 2013), hence indicating there may not be a 
positive linear relationship between the two.” 
2. Materials and Methods 
2.1. Sample  
Patients with BD were recruited from the metropolitan and surrounding areas 
of Sydney as part of a larger ‘Youth Mental Health’ cohort study (Hermens et al., 
2011; Lee et al., 2013; Scott et al., 2013). All patients were referred by a psychiatrist 
who made a diagnosis of a bipolar disorder using DSM-IV criteria (APA, 2000) as 
follows: bipolar I (n = 14), bipolar II (n = 15), bipolar not otherwise specified (n = 4), 
or bipolar spectrum with family history of BD (n =2), defined as an illness pattern 
consisting of periods of both elevated and depressed mood consistent with a bipolar 
spectrum disorder (Angst, 2007).  To confirm diagnosis, a research psychologist 
subsequently conducted a structured interview including the Hamilton Depression 
Rating Scale (HDRS; (Hamilton, 1967)), the Brief Psychiatric Rating Scale (BPRS; 
Overall and Gorham, 1962)) and the Young Mania Rating Scale (YMRS; Young et 
al., 1978). Controls were recruited from the community via word of mouth and local 
newspaper advertisement. Patients and controls were then selected from the Youth 
Mental Health database for the current study based on whether they fitted the age 
range for the study (18 – 30 years) and had an MMN acquisition within 3 months of 
1H-MRS. 
Mood state at time of testing was determined based on an algorithm using 
patients YMRS and HDRS scores, with a YMRS total score greater than 12 
suggestive of elevated mood (Young et al., 1978) and a HDRS score greater than 16 
suggestive of moderate depression (Zimmerman et al., 2013). Mood states were 
defined as follows: euthymic, YMRS total score less than 12 (Young et al., 1978) and 
HDRS less than 17; hypomanic, YMRS greater than 11 and HDRS less than 17; 
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depressed, YMRS less than 12 and HDRS greater than 16; and mixed mood state, 
YMRS was greater than 11 and HDRS greater than 16. Patients’ normal psychotropic 
medication regimens were not interrupted in any way.  
Exclusion criteria for patients and controls were medical instability (i.e. not 
medically or mentally well enough to complete the assessment), history of 
neurological disease, medical illness known to impact cognitive and brain function, 
intellectual disability and insufficient English for assessment. All participants were 
asked to abstain from drug or alcohol use for 48 hours prior to testing and informed 
that they may be asked to under-take an alcohol breath test and/or a saliva drug screen 
if the researcher had reason to believe the participant was under the influence or 
intoxicated. 
The University of Sydney ethics committee approved the study. Participants 
gave written informed consent before participation. 
 
2.2. Self-report measures 
 Participants completed a self-report questionnaire which contained 
demographic information such as age, gender and years of education as well as the 
Alcohol Use Disorders Identification Test (AUDIT), items from the WHO-ASSIST 
(Edwards et al., 2003), the depression anxiety stress scale (DASS; Lovibond and 
Lovibond, 1995) and the Kessler-10 (K-10), a psychological distress scale (Kessler et 
al., 2002).  
  
2.3. Neurophysiological measures 
Participants were fitted with a 64-channel Quik-Cap (Neuroscan) and 
headphones and told they will be watching a silent movie for 20 minutes and they will 
be asked to report back the storyline at the end of the task. Participants were then 
presented with 2,500 binaural pure tones (1,000 Hz, 75 dBSPL, 10 ms rise/fall) with 
stimulus onset asynchrony of 500ms. Two hundred of these tones were duration 
deviant tones (100ms) presented pseudo-randomly within 2,300 standard tones 
(50ms).  
Continuous EEG activity was recorded from sites according to the standard 
10–20 International system (including mastoids), referenced to a nose electrode. 
Activity was sampled and digitized at 500Hz (SynAmps2, Scan 4.3.1 software) and 
filtered using a bandpass filter (0.1 – 30Hz). Data were processed offline using 
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Neuroscan Scan 4.3.1 (Compumedics, Charlotte, North Carolina) software. Epochs 
were constructed at -100 to 450ms relative to stimulus onset and baseline corrected. 
MMN was derived from Fz (frontal site), Cz (central site), M1 (left temporal site) and 
M2 (right temporal site). Epochs that contained activity ± 100 μV at these sites were 
rejected. Additional electrodes were placed above and below the left eye and at the 
outer canthi of both eyes to monitor for eye-blink artifacts and contaminated data was 
corrected using established algorithms (Semlitsch et al., 1986). Mismatch difference 
waveforms were obtained by subtracting waveforms elicited by standards from those 
elicited by duration-deviant stimuli. Peak amplitude was chosen as the primary 
outcome measure to maintain consistency with our previous MMN studies, and was 
determined using automated peak picking within an established epoch window of 
135–205ms (Hermens et al., 2010; Kaur et al., 2011; Kaur et al., 2012b). 
 
2.4 1H-MRS data acquisition  
Imaging was conducted within three months of EEG recording (mean difference in 
days = 10.8, SD = 21.7). Participants were scanned on a 3Tesla GE Discovery MR750 
MRI (GE Medical Systems, Milwaukee, WI). Firstly, a 3D sagittal whole-brain scout 
was undertaken for orientation and positioning of scans (TR=50ms; TE=4ms; 
256matrix; no averaging, z=5mm thickness). Next a T1-weighted Magnetization 
Prepared RApid Gradient-Echo (MPRAGE) sequence producing 196 sagittal slices 
(TR=7.2ms; TE=2.8ms; flip angle = 10°; matrix 256x256; 0.9mm isotropic voxels) 
was acquired for the purpose of localization of the hippocampus. A 1.5 x 3.0 x 1.0 cm 
voxel was placed in the left hippocampus (Figure 1 insert). Spectroscopy data was 
acquired using Point-RESolved Spectroscopy (PRESS) with the following 
parameters; TE=35ms, TR=2000ms, 128 averages, along with two chemical shift-
selective imaging pulses for water suppression. All spectra were shimmed to achieve 
full-width half maximum (FWHM) of <13Hz and visually inspected by independent 
raters. Data with Cramer–Rao Lower Bound greater than 20% were excluded. 
Hippocampal data could not be grey matter (GM)-corrected due to the angulation of 
the acquisition voxel. However since hippocampal tissue composition is 
predominantly GM, left hippocampal volumes were calculated and used as a proxy 
for individual differences. 
2.5 1H-MRS data processing 
Data were transferred offline for post processing using the LCModel software 
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package (Provencher, 1993). All spectra were quantified using a GAMMA-simulated 
PRESS TE 35 basis set of 15 metabolites (including Glu, Glx, N-acetylaspartate 
[NAA] and Inositol [Ins]) and incorporated macromolecule and baseline fitting 
routines (for spectra see Figure 1). Metabolite concentrations were determined as a 
relative ratio to creatine-phosphocreatine (Cr). We also calculated Glu/H20 to assess 
whether results differed when normalising to water instead of Cr. 
Spectra with the following features were excluded from selection in the present study: 
Cramer–Rao Lower Bound greater than 20%, poor spectral morphology, poor spectral 
fit, large variation in residuals, poor signal-to-noise ratio and presence of artefact.  
 
2.6 Hippocampal volumes  
Left hippocampal volume was determined using FMRIB Software Library 
(FSL) (Smith, 2002). Subcortical volumes for the left hippocampi were extracted 
using a semi-automated segmentation routine based on the principles of the Active 
Shape and Appearance Models within a Bayesian framework as implemented by 
‘‘FIRST’’ in FSL. As part of the segmentation routines, all data were aligned into the 
MNI standard space, using a 12- degree-of-freedom affine transformation. A mask 
based on shape models and voxel intensities was then applied to isolate the 
subcortical structures. Absolute volumes of the left hippocampi were then calculated 
from spatially transformed original data using FIRST as implemented in FSL. Finally, 
a boundary correction (z -value =3) was applied (corresponding to a 99.998% 
certainty) to determine the boundary voxels. Data were visually inspected for errors. 
 
2.7. Statistical analyses 
Statistical analyses were carried out using SPSS for Windows 21.0 (SPSS Inc., 
Chicago, Illinois, USA). Group differences in demographics, clinical measures, 
alcohol and tobacco use, neurophysiological measures, metabolite concentrations and 
left hippocampal volumes were assessed by independent t-test or χ2 tests where 
relevant. Homogeneity of variance was determined using the Levene test. If the 
assumption of homogeneity was violated, Welch’s statistic was used to adjust degrees 
of freedom and p-values. Values for MMN, 1H-MRS concentrations and hippocampal 
volumes were converted to z-scores to inspect for outliers (a z-score of +/- 3.00). 
Outliers were then removed from subsequent analysis to reduce the impact of 
influential cases. 
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Pearson’s correlations were performed for the entire sample; co-varying for 
age, hippocampal volume and smoking status. A simple bootstrapping method based 
on 1000 samples was used to obtain bias-corrected and accelerated (BCa) 95% 
confidence intervals. These correlations were also performed for BD and controls 
separately. Alpha was set to 0.05 and BCa 95% confidence intervals were also used to 
assess significance. 
Post-hoc analysis was then conducted to assess the influence of different 
psychotropic medication classes on the MMN and hippocampal-Glu correlations. 
These correlations were re-analysed three times as follows: 1) excluding those on an 
antipsychotic; 2) excluding those on an anticonvulsant; and 3) excluding those on an 
antidepressant. 
 
3. Results 
3.1. Demographics, symptoms and medications 
Seventy-one participants (41 BD and 30 controls) were selected from the 
Youth Mental Health database having had MMN and 1H-MRS conducted within 3 
months and fitting the age criteria for the study. From those selected, valid 
hippocampal Glu data was available for 33 participants with BD and 23 controls. 
There were no significant differences in demographics and symptom scores between 
those who had valid (n = 56) vs. invalid data (n = 15). However BD participants 
excluded due to invalid data had a significantly longer duration of illness.  See 
supplementary material for these statistical analyses as well as detailed reasons for 
invalid and excluded data. 
The demographics and symptom scores for included participants are shown in 
Table 1. There were no differences in age, gender, proportion of smokers, and alcohol 
use between BD and controls. As expected, t-test revealed significant differences in 
K-10 and DASS scores and years of education, with BD showing higher symptom 
scores and lower years of education. 
The average BPRS scores suggest that on average the patient population was 
moderately ill according to the Clinical Global Impression equivalent (Leucht et al., 
2005), with the highest score in the markedly ill range (BPRS = 54) and the lowest 
score in the normal range (BPRS = 24). 
At the time of testing 17 (51.5%) patients were taking antidepressants, 14 
(42.4%) were on anti-convulsants, ten (30.3%) patients were on atypical 
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antipsychotics, nine (27.3%) were on lithium, one (3.0%) was on benzodiazepine and 
one was on a simulant. Seven (21.2%) patients were medication free.  
 
3.2. Neurophysiology, structural imaging and spectroscopy results 
There were no outliers in terms of M1 amplitude (z-score range: -1.77 to 
2.76), M2 amplitude (-1.86 to 1.82), Glu/Cr (-1.66 to 2.55) or hippocampal volume (-
2.34 to 2.11). Table 2 shows the results from the t-test for between-group differences 
in the neurobiological measures. There were no significant differences between BD 
and controls in metabolite concentrations, hippocampal volumes, average epochs 
accepted for MMN or temporal MMN amplitude (see Figure 2 for waveforms). BD 
and controls also did not differ in times between MMN and 1H-MRS acquisitions (t 
(54) = -0.849, p > 0.05). 
The correlation matrix is shown in Table 3. The combined analysis (patients 
and controls) showed a statistically significant correlation between Glu/Cr at M1, and 
trend level at M2 (p < 0.1).  In controls, a significant correlation was found between 
M1 and Glu/Cr and a trend was found between M2 and Glu/Cr (p < 0.1). There were 
no significant correlations in BD. Scatterplots for left temporal MMN vs Glu/Cr are 
shown in Figure 3.                           
 
3.3 Post-hoc analysis 
 In order to further assess the aforementioned non-significant correlations in 
BD we re-analysed the correlations between M1 and Glu/Cr excluding patients on 
different classes of psychotropic medications. The correlations remained non-
significant when excluding patients on an antipsychotic (r = 0.117, p > 0.05, 95% BI: 
-0.44, 0.58) and patients on an anticonvulsant (r = 0.139, p >0.05, 95% BI: -0.43, 
0.69). When excluding patients on an antidepressant a trend-level positive correlation 
was observed (r = 0.490, p < 0.1, 95% BI: -0.22, 0.87). 
 All results remained significant when we re-ran the correlations normalised to 
water instead of Cr (see Supplementary Table 2). 
 
4. Discussion  
To our knowledge, this is the first study to look at the relationship between 
MMN and in vivo concentrations of Glu/Cr in BD. We sought to explore this 
relationship in order to shed light on hippocampal Glu/NMDA receptor disturbances 
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in the disorder. The results of our study demonstrate the presence of an association 
between the aforementioned variables in control subjects, but not in BD, and thus 
provide important considerations and avenues for further research. Firstly, these 
findings provide new insight into the neurophysiology of MMN, with evidence 
supporting a relationship between Glu concentration in the hippocampus and temporal 
MMN amplitude. Furthermore, the lack of a correlation (in either group) between 
frontal MMN and hippocampal-Glu suggests that this association is localised to the 
temporal region. Secondly, our data demonstrate that the metabolite system regulating 
MMN is disturbed in BD, irrespective of differences in MMN amplitude, metabolite 
concentrations or hippocampal volume, none of which were significantly different 
between the groups. Thirdly, through integrated interpretation of these measures we 
provide possible neurochemical hypotheses for the basis of hippocampal Glu/NMDA 
abnormalities in BD. It is important to note that due to the variation in time between 
MMN and 1H-MRS acquisitions in the present study (i.e. up to 3 months), any 
assumptions about the potential state related associations between these measures 
should be made with caution. Despite this, there evidence from similar research 
(Stone et al., 2010) to suggest that the relationship between these measures is better 
accounted for by the trait-related aspects of the underlying neurobiology. 
The results demonstrate that within a “healthy” range of temporal-MMN 
amplitudes and in vivo Glu concentrations, an increased MMN is associated with an 
increased Glu/Cr. This association is in line with the predominant neurochemical 
hypothesis of MMN generation, namely, that MMN represents Glu signalling through 
the NMDA receptor (Garrido et al., 2009; Javitt et al., 2011; Kenemans and 
Kahkonen, 2011). Specifically, higher levels of Glu would result in greater NMDA 
receptor activation and accordingly, increased MMN amplitude. This is in agreement 
with research by Stone et al., (2010), who reported a positive association between in 
vivo Glx and MMN in the thalamus of prodromal patients. It is noteworthy that in the 
present study the 1H-MRS voxel was located in the left hippocampus, and 
accordingly, the association between left temporal MMN amplitude was stronger than 
with right temporal MMN in controls and there was no relationship between 
frontocentral MMN and hippocampal-Glu. This underscores the idea of two dipolar 
sources of MMN located in the temporal lobes of each hemisphere (Rinne et al., 
2000).  
As hypothesised there were no significant associations between Glu/Cr and 
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temporal MMN in BD but surprisingly, the patients in the present sample did show a 
significantly higher frontal MMN than controls which is in contrast to our previous 
meta-analysis of this measure in BD (Chitty et al., 2013), the reason for this is unclear 
and warrants further investigation. However, there were no group differences in 
temporal MMN amplitudes, neurometabolites of interest or hippocampal volume. In 
light of the positive and significant temporal correlation in controls, these null 
findings are consistent with the BD model of neuroprogression, which proposes that 
as the illness progresses so do underlying neurobiological changes associated with 
more chronic presentations of the disorder (Berk et al, 2011). Hence in the present 
sample consisting of patients in early stages of BD, pathophysiological changes may 
not be distinct enough to differ from matched controls. This may suggest that 
deregulation in the Glu/NMDA system precedes impairments in Glu levels or MMN 
previously reported in BD samples (for a review see Chitty et al., 2013).  
Alternatively, these results could suggest that MMN in BD is influenced by 
different neurochemicals. Indeed, there are other theories behind the pharmacological 
generation of MMN, not only in terms of other neurobiological systems, such as 
GABA, serotonin and dopamine (Garrido et al., 2009; Kenemans and Kahkonen, 
2011), but also at the level of the NMDA receptor. Modulation of NMDA receptor 
function is complex, with multiple regulatory sites embedded within the ionophore. 
One such modulatory chemical that has received recent attention is glutathione 
(GSH), the brains primary anti-oxidant. Accordingly, a recent study has found a 
positive correlation between serum GSH and MMN amplitude in controls (Ballesteros 
et al., 2013), and another has shown that treatment with N-acetyl cysteine (NAC), a 
precursor for GSH synthesis, can increase MMN amplitudes in schizophrenia (Lavoie 
et al., 2008). It should be noted that NAC is believed to be taken up through the Glu-
cysteine exchanger, resulting in a higher amount a Glu release into the extrasynaptic 
space (Bauzo et al., 2012; Javitt et al., 2011), and hence, the latter finding is in 
agreement with the present result in controls.  
Use of psychotropic medications could be another potential cause for the non-
significant correlations seen in patients, with all but seven of our BD participants 
medicated at time of testing. Psychotropic medications may impact metabolite levels 
and as a result, the entire MMN regulatory system. That said if psychotropic 
medications do affect our neurobiological measures of interest it is not evident in 
between-group differences in this sample of young people. However in our post hoc 
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analysis to address this issue, we did note a trend-level positive correlation in BD 
between M1 and Glu/Cr (similar to that seen in controls) when excluding the 17 
patients on anti-depressants. This highlights a potential role for anti-depressants in the 
“deregulation” between Glu/Cr and M1 amplitude. Readers should bear in mind that 
with our relatively low sample size we were unable to thoroughly assess the influence 
of different subtypes of medications on the correlations and this is an avenue that 
requires further investigation. There are some limitations in this study. Firstly, 41% of 
participants did not have their EEG and 1H-MRS acquired within a 24-hour period. 
The degree to which Glu/Cr concentrations change over time is unclear, so there is a 
possibility that the concentrations of this neurometabolite may have changed between 
the recordings. Future studies that determine the amount of change in each of these 
measures over time would be of considerable importance.   
Secondly, there are some limitations concerned with our 1H-MRS procedure. 
We are not able to quantify absolute concentration of Glu, so we used ratio over Cr. 
This method is considered to be disadvantageous due to reported differences in frontal 
Cr in BD (Frey et al., 2007; Frye et al., 2007), though to our knowledge this has not 
been found in the hippocampus, nor were there any differences in Cr concentration 
between groups in the present study. It should be noted that hippocampal data was not 
GM-corrected, which presents a limitation to the analysis in this region. Thirdly, 
readers should be advised that a structured research diagnostic interview was not part 
of the clinical assessment, and therefore the reliability of the diagnoses made in this 
study may be limited. Finally, as our study into the relationship between MMN and 
1H-MRS was largely exploratory we have undertaken multiple correlations to explore 
our hypotheses and not corrected alpha, hence there is a risk of Type I error. 
4.3 Conclusion 
The results from this study suggest that regulation of temporal MMN by Glu is 
abnormal in BD. Our data does not allow us to make any firm statements as to why 
this occurs, or importantly, how it may be treated. Future studies should aim to collect 
MMN and 1H-MRS data simultaneously in order to better define these associations. 
The seemingly disparate and unconnected Glu/MMN system in BD noted here 
may indicate a lack of tightly regulated NMDA functioning in the hippocampus, and 
hence provides insight into the underlying basis of glutamatergic transmission 
disturbances implicated in the disorder 
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Table 1: Demographic and symptoms scores for each group, tested using t-test or chi-square 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*p< 0.05, **p < 0.01, ***p <0.001 
AUDIT, alcohol use disorder identification test; BPRS, brief psychiatric rating scale; DASS, depression anxiety stress 
scales; HDRS, Hamilton depression rating scale; K-10, Kessler psychological distress scale; Mood state, mood state at 
time of testing.  
Note: HAM-D, BPRS, YMRS scores were not conducted within 2 weeks of MRI for 6 patients and therefore their 
scores and mood states were not included. K-10 and DASS scores are missing for 2 patients and 2 controls 
 
 
  
 BD 
(n = 33 ) 
Controls 
(n = 23) 
t /  χ2 
Sex ratio  (M: F) 7:26 7:16 χ2 (1) = 0.62 
Age (SD) 23.3 (3.5) 24.3 (2.8) t (54) = 1.13 
Years of education (SD) 13.1 (2.1) 14.3 (2.2) t (54) = 2.15* 
AUDIT total score (SD) 9.42 (8.1) 9.17 (5.6) t (54) = 0.05 
Current tobacco smokers (%) 16 (48.5) 8 (24.8) χ2 (1) = 1.04 
K-10 24.9 (8.3) 14.0 (4.2) t (46.7) = 6.4*** 
DASS – Stress (SD) 17.6 (11.8) 7.05 (7.0) t (49.4) = 4.2*** 
DASS – Anxiety (SD) 10.7 (7.2) 4.10 (4.9) t (50) = 4.1*** 
DASS – Depression (SD) 15.4 (13.3) 2.10 (2.3) t (32.6) = 5.6*** 
HDRS – Total (SD) 9.15 (7.7)   
BPRS – Total (SD) 35.9 (8.5)   
YMRS – Total (SD) 4.63 (5.3)   
Duration of illness, y (SD) 8.0 (3.8)   
Mood state, n (%)    
Euthymic 12 (36.4)   
Hypomanic 2 (6.1)   
Depressed 11 (33.3)   
Mixed 2 (6.1)   
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Table 2: MMN amplitudes, metabolite concentrations and hippocampal volume 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* p <0.05 
& out of 200 duration deviant tones presented pseudo-randomly within 2300 standard tones 
$ data available for 28 patients and 21 controls  
BD, bipolar disorder; Cr, creatine; Glu, glutamate; Glx, combined glutamate and glutamine signal; Ins, 
Inositol; M1, left temporal; M2, right temporal; MMN, mismatch negativity; NAA, N-acetylaspartate. 
 
  
 BD 
(n = 33) 
Controls 
(n = 23) 
t  
M1 MMN amplitude (μV) 2.23 (1.3) 2.70 (1.5) t (54) = 1.22 
M2 MMN amplitude (μV) 2.22 (1.3) 2.54 (1.2) t (54) = 0.94 
Fz MMN amplitude (μV) -4.21 (1.8) -5.62 (2.3) t (54) = 1.69* 
Cz MMN amplitude (μV) -4.01 (2.1) -5.01 (2.2) t (54) = 1.69 
Average epochs accepted& 181.5 (24.0) 189.1 (10.3) t (54) = 1.43 
Hippocampal [Glu/Cr] 1.48 (0.20) 1.49 (0.18) t (54) = 0.20 
Hippocampal [Cr] 10.5 (1.2) 10.5 (1.1) t (54) = 0.15 
Hippocampal [Glx/Cr]$ 1.79 (0.34) 1.71 (0.22) t (47) = 0.97 
Hippocampal [NAA/Cr]$ 1.20 (0.11) 1.27 (0.15) t (47) = 1.76 
Hippocampal [Ins/Cr]$ 1.08 (0.16) 1.06 (0.15) t (47) = 0.43 
Hippocampal volume  (mm3) 3873 (416) 3862 (484) t (54) = 0.09 
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Table 3: Correlation matrix between temporal MMN and neurometabolite concentration in the 
hippocampus 
 
 
 
 
# p < 0.1; * p <0.05 
$ data available for 28 patients and 21 controls  
BD, bipolar disorder; Cr, creatine; Cz, central mismatch negativity amplitude; Fz, frontal 
mismatch negativity amplitude; Glu, glutamate; Glx, overlapping resonance of glutamate-
glutamine; MMN, mismatch negativity; M1, left temporal mismatch negativity amplitude; M2, 
right temporal mismatch negativity. 
 
  
  M1 M2 Fz Cz 
  r BCa 
95% 
C.I 
r BCa 
95% 
C.I 
r BCa 
95% 
C.I 
r BCa 
95% 
C.I 
Glu/Cr Whole 
sample 
0.292* 0.017, 
0.52 
0.235# -0.07, 
0.53 
-
0.068 
-0.39, 
0.27 
-
0.006 
-0.29, 
0.31 
Controls 0.512* 0.15, 
0.78 
0.469* -0.12, 
0.83 
-
0.166 
-0.62, 
0.55 
-
0.141 
-0.61, 
0.46 
BD 0.147 -0.25, 
0.48 
0.115 -0.27, 
0.45 
-
0.040 
-0.42, 
0.40 
0.062 -0.31, 
0.41 
Glx/Cr$ Whole 
sample 
0.161 -0.20, 
0.47 
0.070 -0.26, 
0.367 
-
0.244 
-0.53, 
0.06 
-
0.252 
-0.54, 
0.03 
Controls 0.494* 0.03, 
0.77 
0.248 -0.38, 
0.69 
-
0.195 
-0.79, 
0.48 
-
0.245 
-0.74, 
0.30 
BD 0.060 -0.48, 
0.52 
0.102 -0.45, 
0.51 
-
0.278 
-0.67, 
0.17 
-
0.269 
-0.65, 
0.16 
      24 
 
 
Figure 1: Water supressed glutamate spectra sampled from the left hippocampus, processed 
using LCModel. The glutamate metabolite peak is resolved at around 2.35ppm. The insert 
shows a sagittal view of the representative T1-weighted image illustrating the voxel size (1.5 x 
3.0 x 1.0 cm) and placement for the hippocampus.  
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Figure 2: Average event-related potentials for controls (grey line) and BD (black line) at left 
temporal (M1) and right temporal (M2) electrode sites.  
Note that the MMN waveforms recorded at M1 and M2 are reversed in polarity. 
 
BD, bipolar disorder; M1, left temporal; M2, right temporal; MMN, mismatch negativity; msec, 
milliseconds; μV, microvolts 
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Figure 2: Scatterplot of hippocampal Glu/CrPCr vs. peak MMN amplitude at the left temporal 
site in controls (grey triangles and grey line) and BD (black circles and black line).  
BD, bipolar disorder; Glu/CrPCr, glutamate/creatine-phosphocreatine; I.U., international units; 
MMN, mismatch negativity. 
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Supplementary Material 1: Inclusion vs exclusion 
 
 
p< 0.05* 
& Categories are not mutually exclusive 
$ Only relevant for proportion of sample with bipolar disorder, n = 8 excluded and n = 33 included. 
BD, bipolar disorder; BPRS, brief psychiatric rating scale; DASS, depression anxiety stress scales; HC, healthy controls; 
HDRS, Hamilton depression rating scale;  
K-10, Kessler psychological distress scale 
 
 
 Excluded  
(n =15) 
Included  
(n=56) 
t /  χ2 
 
Reasons for exclusion (n)& Cramer–Rao Lower Bound greater than 20% (7) N/A N/A 
Artifact (7) N/A  N/A 
Poor spectra morphology (9) N/A  N/A 
Poor fit to raw data (3) N/A N/A 
 Large variation in residuals (1) N/A N/A 
Age (SD) 24.2 (2.8) 23.7 (3.3) t (69) = 0.58  
M:F 6:9 14:42 χ2  (1) = 1.32 
BD:HC 8:7 33:23 χ2  (1) = 0.15 
Years of education 13.5 (2.5) 13.5 (2.2) t (66) = 0.13  
K-10 (SD) 23.2 (18.1) 20.5 (8.7) t (62) = 1.05  
DASS – Stress (SD) 15.5 (10.3) 13.3 (11.3) t (62) = 0.60 
DASS – Anxiety (SD) 6.83 (6.7) 8.04 (7.1) t (62) = 0.53 
DASS – Depression (SD) 13.7 (11.7) 10.0 (12.3) t (62) = 0.93 
HDRS – Total (SD) 7.56 (8.4) 6.24 (7.2) t (57) = 0.49 
BPRS – Total (SD) 36.1 (13.9) 31.9 (8.35) t (57) = 1.24 
Duration of illness, y (SD) $ 9.63 (1.3) 7.97 (3.8) t (38) = 1.22* 
